← Leaderboards
Charles W. Flexner
Johns Hopkins University
$41,000,447
Attributed
$55,498,173
Total exposure
40
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,498,173 · 40
By mechanism
UM1$31,731,580 · 1
U01$15,264,456 · 2
R24$7,484,712 · 1
M01$1,017,425 · 36
Top collaborators
- Amita Gupta14 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Amita Gupta$24,858,182
- Jenell S Coleman$4,734,272
- Chi V. Dang$24,535,395
- Charlotte Ann Gaydos$11,731,089
- Eric Slade$6,790,926
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationClinical TrialsAids TherapyResourcesCommunitiesResearch PersonnelAids PreventionDrug Screening /EvaluationClinical Trial Phase IAdolescentInfectionAdultChildhoodPreventionAids Clinical Trial GroupAidsCombination ChemotherapyAntiviral AgentsAntiaids AgentPharmacokineticsUnited States National Institutes Of Health
Grant awards (112)
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$2,442,720
UM1 · FY2025 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$1,181,637
R24 · FY2025 · AI · contact PI
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$2,176,002
UM1 · FY2024 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$796,698
R24 · FY2024 · AI · contact PI
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$144,480
UM1 · FY2024 · AI
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$2,099,237
UM1 · FY2023 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$828,733
R24 · FY2023 · AI · contact PI
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$2,082,659
UM1 · FY2022 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$687,523
R24 · FY2022 · AI · contact PI
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)$2,002,610
UM1 · FY2021 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$709,629
R24 · FY2021 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$2,786,855
UM1 · FY2020 · AI · contact PI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$764,020
R24 · FY2020 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$460,679
UM1 · FY2020 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$3,352,002
UM1 · FY2019 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$485,255
R24 · FY2019 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$2,136,131
UM1 · FY2018 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$485,255
R24 · FY2018 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$1,987,063
UM1 · FY2017 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$580,299
R24 · FY2017 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$54,956
R24 · FY2017 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$2,525,176
UM1 · FY2016 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$485,255
R24 · FY2016 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$1,871,345
UM1 · FY2015 · AI · contact PI
Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)$425,452
R24 · FY2015 · AI · contact PI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)$2,928,493
UM1 · FY2014 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,038,077
UM1 · FY2013 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,698,051
UM1 · FY2012 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,346,297
U01 · FY2011 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,048,057
U01 · FY2010 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,603,399
U01 · FY2009 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,413,300
U01 · FY2009 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,388,423
U01 · FY2008 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$69,143
U01 · FY2008 · AI · contact PI
Johns Hopkins AIDS Clinical Trials Unit$1,034,929
U01 · FY2007 · AI · contact PI
ACTG A5191$48,518
M01 · FY2007 · RR · contact PI
ACTG A5001$33,471
M01 · FY2007 · RR · contact PI
ACTG A5128$4,606
M01 · FY2007 · RR · contact PI
ACTG 362$3,071
M01 · FY2007 · RR · contact PI
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$905,675
U01 · FY2006 · AI · contact PI
ACTG A5191$261,022
M01 · FY2006 · RR · contact PI
ACTG A5001$49,040
M01 · FY2006 · RR · contact PI
ACTG A5128$21,621
M01 · FY2006 · RR · contact PI
ACTG A5223$6,855
M01 · FY2006 · RR · contact PI
ACTG 362$5,273
M01 · FY2006 · RR · contact PI
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,132,476
U01 · FY2005 · AI
ACTG A5191$237,468
M01 · FY2005 · RR
ACTG A5001$72,242
M01 · FY2005 · RR
ACTG A5128$22,172
M01 · FY2005 · RR
INTERACTION OF AMPRENAVIR (APV), LOPINAVIR (LPV/R), AND EFAVIRENZ (EFV)$11,443
M01 · FY2005 · RR
ACTG 5077: VIROLOGIC STUDIES$10,729
M01 · FY2005 · RR
ACTG 362$7,869
M01 · FY2005 · RR
ORAL CLOTRIMAZOLE$2,860
M01 · FY2005 · RR
ACTG SCREENING CONSENT$2,146
M01 · FY2005 · RR
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,032,476
U01 · FY2004 · AI
Oral Clotrimazole$64,119
M01 · FY2004 · RR
ACTG A5191$48,500
M01 · FY2004 · RR
ACTG A5001$31,649
M01 · FY2004 · RR
Interaction of Amprenavir (APV), Lopinavir (LPV/r), and Efavirenz (EFV)$30,416
M01 · FY2004 · RR
ACTG 5077: Virologic Studies$24,661
M01 · FY2004 · RR
ACTG 372$6,165
M01 · FY2004 · RR
ACTG 362$4,110
M01 · FY2004 · RR
ACTG A5043$3,289
M01 · FY2004 · RR
ACTG Screening Consent$1,644
M01 · FY2004 · RR
ACTG 384$1,233
M01 · FY2004 · RR
A5058s: Augmentation of HIV-Specific Helper and CTL Response through Therapeutic$822
M01 · FY2004 · RR
ANTIRETROVIRAL RESPONSE TO IDV/RTV CONTAINING REGIMEN IN HIV-INFECTED SUBJECTS$411
M01 · FY2004 · RR
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,478,841
U01 · FY2003 · AI
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,280,720
U01 · FY2002 · AI
ACT 307--SAFETY/ANTIRETROVIRL ACTIVITY OF HYDROXYUREA ALONE/COMBINATION WITH DDI$0
M01 · FY2002 · RR
SAFETY AND ANTIRETROVIRAL ACTIVITY OF HYDROXUREA AND DIDANOSINE$0
M01 · FY2002 · RR
SAFETY AND EFFICACY OF RITONAVIR IN COMBINATION WITH NELFINAVIR IN HIV$0
M01 · FY2002 · RR
PHARMACOKINETIC ACTION--PROTEASE INHIBITORS &ANTILIPIDS$0
M01 · FY2002 · RR
PROTEASE/NONNUCLEOSIDE TRANSCRIPTASE/NUCLEOSIDE HIV THER$0
M01 · FY2002 · RR
HIV PROTEASE INHIBITOR &METHADONE METABOLISM IN HIV$0
M01 · FY2002 · RR
BLOOD LYMPHOCYTES FROM HIV--CORECEPTOR VIRUS ISOLATION$0
M01 · FY2002 · RR
AMPRENAVIR IN COMBO WITH ABACAVIR/EFAVIRENZ/ADEFOVIR$0
M01 · FY2002 · RR
NELFINAVIR INDUCED DIARRHEA--SECRETORY VS NONSECRETORY$0
M01 · FY2002 · RR
TRIAL OF HYDROXYUREA IN COMBO WITH ANTIVIRALS IN HIV$0
M01 · FY2002 · RR
TRIAL OF EFV/NFV IN COMBO WITH ZDV/3TC/IDV IN AIDS$0
M01 · FY2002 · RR
ACTG 892--ANTIRETROVIRAL THERAPY EFFECTS ON LEAN BODY$0
M01 · FY2002 · RR
ACTG 365--PHARMACOKINETICS ON INDINAVIR AND RIFABUTIN$0
M01 · FY2002 · RR
FLUCONAZOLE VS EPISODIC IN HIV+ PTS WITH CANDIDIASIS$0
M01 · FY2002 · RR
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,530,720
U01 · FY2001 · AI
SAFETY AND ANTIRETROVIRAL ACTIVITY OF HYDROXUREA AND DIDANOSINE$0
M01 · FY2001 · RR
PHARMACOKINETIC ACTION--PROTEASE INHIBITORS &ANTILIPIDS$0
M01 · FY2001 · RR
PROTEASE/NONNUCLEOSIDE TRANSCRIPTASE/NUCLEOSIDE HIV THER$0
M01 · FY2001 · RR
HIV PROTEASE INHIBITOR &METHADONE METABOLISM IN HIV$0
M01 · FY2001 · RR
BLOOD LYMPHOCYTES FROM HIV--CORECEPTOR VIRUS ISOLATION$0
M01 · FY2001 · RR
AMPRENAVIR IN COMBO WITH ABACAVIR/EFAVIRENZ/ADEFOVIR$0
M01 · FY2001 · RR
NELFINAVIR INDUCED DIARRHEA--SECRETORY VS NONSECRETORY$0
M01 · FY2001 · RR
TRIAL OF HYDROXYUREA IN COMBO WITH ANTIVIRALS IN HIV$0
M01 · FY2001 · RR
TRIAL OF EFV/NFV IN COMBO WITH ZDV/3TC/IDV IN AIDS$0
M01 · FY2001 · RR
ACTG 892--ANTIRETROVIRAL THERAPY EFFECTS ON LEAN BODY$0
M01 · FY2001 · RR
ACTG 365--PHARMACOKINETICS ON INDINAVIR AND RIFABUTIN$0
M01 · FY2001 · RR
FLUCONAZOLE VS EPISODIC IN HIV+ PTS WITH CANDIDIASIS$0
M01 · FY2001 · RR
ACT 307--SAFETY/ANTIRETROVIRL ACTIVITY OF HYDROXYUREA ALONE/COMBINATION WITH DDI$0
M01 · FY2001 · RR
SAFETY AND EFFICACY OF RITONAVIR IN COMBINATION WITH NELFINAVIR IN HIV$0
M01 · FY2001 · RR
ACTG 365--PHARMACOKINETICS ON INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR
ACT 307--SAFETY/ANTIRETROVIRL ACTIVITY OF HYDROXYUREA ALONE/COMBINATION WITH DDI$0
M01 · FY2000 · RR
SAFETY AND EFFICACY OF RITONAVIR IN COMBINATION WITH NELFINAVIR IN HIV$0
M01 · FY2000 · RR
SAFETY AND ANTIRETROVIRAL ACTIVITY OF HYDROXUREA AND DIDANOSINE$0
M01 · FY2000 · RR
PHARMACOKINETIC ACTION--PROTEASE INHIBITORS &ANTILIPIDS$0
M01 · FY2000 · RR
PROTEASE/NONNUCLEOSIDE TRANSCRIPTASE/NUCLEOSIDE HIV THER$0
M01 · FY2000 · RR
HIV PROTEASE INHIBITOR &METHADONE METABOLISM IN HIV$0
M01 · FY2000 · RR
BLOOD LYMPHOCYTES FROM HIV--CORECEPTOR VIRUS ISOLATION$0
M01 · FY2000 · RR
AMPRENAVIR IN COMBO WITH ABACAVIR/EFAVIRENZ/ADEFOVIR$0
M01 · FY2000 · RR
NELFINAVIR INDUCED DIARRHEA--SECRETORY VS NONSECRETORY$0
M01 · FY2000 · RR
TRIAL OF HYDROXYUREA IN COMBO WITH ANTIVIRALS IN HIV$0
M01 · FY2000 · RR
TRIAL OF EFV/NFV IN COMBO WITH ZDV/3TC/IDV IN AIDS$0
M01 · FY2000 · RR
ACTG 892--ANTIRETROVIRAL THERAPY EFFECTS ON LEAN BODY$0
M01 · FY2000 · RR
FLUCONAZOLE VS EPISODIC IN HIV+ PTS WITH CANDIDIASIS$0
M01 · FY2000 · RR